Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Leukemia

Volumn 31, Issue 10, 2017, Pages 2094-2103

  Flores Montero, J ^a   Sanoja Flores, L ^a   Paiva, B ^b   Puig, N ^c   Garcia Sanchez O ^c   Bottcher S ^d   Van Der Velden, V H J ^e   Perez Moran J J ^c   Vidriales, M B ^c   Garcia Sanz R ^c   Jimenez, C ^c   Gonzalez M ^c   Martinez Lopez J ^f   Corral Mateos, A ^a   Grigore, G E ^g   Fluxa R ^g   Pontes, R ^h   Caetano, J ⁱ   Sedek, L ^j   Del Canizo M C ^c   Blade J ^k   Lahuerta, J J ^f   Aguilar, C ^l   Barez A ^m   Garcia Mateo A ⁿ   Labrador, J ^o   Leoz, P ^a   Aguilera Sanz, C ^p   San Miguel, J ^b   Mateos, M V ^c   Durie, B ^q   Van Dongen, J J M ^e,r   Orfao, A ^a   more..

^a CSIC   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Cytognos SL   (Spain)

^h FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^j MEDICAL UNIVERSITY OF SILESIA   (Poland)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL SANTA BÁRBARA   (Spain)

^m Hospital Provincial   (Spain)

ⁿ Hospital Complejo Asistencial de Segovia   (Spain)

^o HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^p HOSPITAL EL BIERZO   (Spain)

^q CEDARS SINAI MEDICAL CENTER   (United States)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD38 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; STEM CELL FACTOR RECEPTOR; SYNDECAN 1;

ADULT; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEXT GENERATION FLOW METHOD; PLASMA CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; AGED; ANTIBODY SPECIFICITY; CELL COUNT; DEVICES; EQUIPMENT DESIGN; FEMALE; FLOW CYTOMETRY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SOFTWARE; SPECIMEN HANDLING; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODY SPECIFICITY; CELL COUNT; EQUIPMENT DESIGN; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PLASMA CELLS; SENSITIVITY AND SPECIFICITY; SOFTWARE; SPECIMEN HANDLING; TREATMENT OUTCOME;

EID: 85014613923     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2017.29     Document Type: Article

References (57)

1. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, et al. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia 2014; 28: 525-542
2. Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015; 126: 300-310
3. Lonial S, Durie B, Palumbo A, San-Miguel J. Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives. Leukemia 2016; 30: 526-535
4. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2016; 91: 101-119
5. Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol L, Sureda A, de la Rubia J, et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782
6. Sonneveld P, Goldschmidt H, Rosinol L, Blade J, Lahuerta JJ, Cavo M, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. J Clin Oncol 2013; 31: 3279-3287
7. Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226-232
8. Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014; 32: 634-640
9. Mateos MV, Leleu X, Palumbo A, San Miguel JF. Initial treatment of transplantineligible patients in multiple myeloma. Expert Rev Hematol 2014; 7: 67-77
10. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet 2015; 385: 2197-2208
11. Mateos MV, Ocio EM, Paiva B, Rosinol L, Martinez-Lopez J, Blade J, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev 2015; 29: 387-403
12. Fulciniti M, Munshi NC, Martinez-Lopez J. Deep response in multiple myeloma: a critical review. BioMed Res Int 2015; 2015: Article ID 832049
13. Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014; 28: 258-268
14. Gay F, Larocca A, Wijermans P, Cavallo F, Rossi D, Schaafsma R, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117: 3025-3031
15. Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. Curing myeloma at last: defining criteria and providing the evidence. Blood 2014; 124: 3043-3051
16. Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood 2015; 125: 3059-3068
17. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 2012; 119: 687-691
18. Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 2011; 29: 1627-1633
19. Paiva B, Montalbán MA, Puig N, Cordon L, Martinez-Lopez J, Ocio EM, et al. Clinical significance of sensitive Flow-MRD monitoring in elderly multiple myeloma patients on the Pethema/GEM2010MAS65 Trial. Blood 2014; 124: 3390
20. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013; 31: 2540-2547
21. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002; 100: 3095-3100
22. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 2015; 125: 1932-1935
23. Robillard N, Bene MC, Moreau P, Wuilleme S. A single-tube multiparameter sevencolour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013; 3: e134
24. Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood 2016; 127: 3165-3174
25. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014; 28: 391-397
26. Sarasquete ME, Garcia-Sanz R, Gonzalez D, Martinez J, Mateo G, Martinez P, et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 2005; 90: 1365-1372
27. Ladetto M, Donovan JW, Harig S, Trojan A, Poor C, Schlossnan R, et al. Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 241-253
28. Puig N, Sarasquete ME, Alcoceba M, Balanzategui A, Chillon MC, Sebastian E, et al. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma. Eur J Haematol 2012; 89: 328-335
29. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014; 123: 3073-3079
30. Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol 2015; 12: 286-295
31. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346
32. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317
33. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, et al. Nextgeneration sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014; 28: 1299-1307
34. Bai Y, Wong KY, Fung TK, Chim CS. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes. J Hematol Oncol 2016; 9: 107
35. Martinez-Lopez J, Fernandez-Redondo E, Garcia-Sanz R, Montalban MA, Martinez-Sanchez P, Pavia B, et al. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study. Br J Haematol 2013; 163: 581-589
36. Rawstron AC, de Tute RM, Haughton J, Owen RG. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the leeds haematological malignancy diagnostic service. Cytometry B Clin Cytom 2016; 90: 54-60
37. van Dongen JJ, van der Velden VH, Bruggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood 2015; 125: 3996-4009
38. Flanders A, Stetler-Stevenson M, Landgren O. Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity. Blood 2013; 122: 1088-1089
39. Salem D, Stetler-Stevenson M, Yuan C, Landgren O. Myeloma minimal residual disease testing in the United States: evidence of improved standardization. Am J Hematol 2016; 91: E502-E503
40. Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, et al. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition. Cytometry B Clin Cytom 2016; 90: 26-30
41. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008; 93: 431-438
42. Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom 2016; 90: 31-39
43. Pedreira CE, Costa ES, Barrena S, Lecrevisse Q, Almeida J, van Dongen JJ, et al. Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A 2008; 73: 834-846
44. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012; 26: 1986-2010
45. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908-1975
46. Pedreira CE, Costa ES, Lecrevisse Q, van Dongen JJ, Orfao A, EuroFlow C. Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol 2013; 31: 415-425
47. Maecker HT, Frey T, Nomura LE, Trotter J. Selecting fluorochrome conjugates for maximum sensitivity. Cytometry A 2004; 62: 169-173
48. Flores-Montero J, de Tute R, Paiva B, Perez JJ, Bottcher S, Wind H, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom 2016; 90: 61-72
49. Orfao De Matos Correia e Vale A, Sobral da Costa E, Pedreira CE Method for the multidimensional detection of aberrant phenotypes in neoplastic cells to be used to monitor minimal disease levels using flow cytometry, European patent 1724581B1 (2014
50. Orfao De Matos A, Pedreira CE, Sobral Da Costa E. Generation of flow cytometry datafiles with a potentially infinite number of dimensions derived from the fusion of a group of separate flow cytometry datafiles and their multidimensional reconstruction with both actually measured and estimated flow cytometry data, European patent EP1770387B1 (2011
51. Pedreira CE, Costa ES, Almeida J, Fernandez C, Quijano S, Flores J, et al. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders. Cytometry A 2008; 73A: 1141-1150
52. Pojero F, Flores-Montero J, Sanoja L, Perez JJ, Puig N, Paiva B, et al. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases. Cytometry B Clin Cytom 2016; 90: 91-100
53. Paiva B, Puig N, Garcia-Sanz R, San Miguel JF. Is this the time to introduce minimal residual disease in multiple myeloma clinical practice? Clin Cancer Res 2015; 21: 2001-2008
54. Rawstron AC, Paiva B, Stetler-Stevenson M. Assessment of minimal residual disease in myeloma and the need for a consensus approach. Cytometry B Clin Cytom 2016; 90: 21-25
55. Silvennoinen R, Lundan T, Kairisto V, Pelliniemi TT, Putkonen M, Anttila P, et al. Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma. Blood Cancer J 2014; 4: e250
56. Wood BL. Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom 2016; 90: 47-53
57. Royston DJ, Gao Q, Nguyen N, Maslak P, Dogan A, Roshal M. Single-Tube 10-fluorochrome analysis for efficient flow cytometric evaluation of minimal residual disease in plasma cell myeloma. Am J Clin Pathol 2016; 146: 41-49